Health Economics›Small cell lung cancer›Extensive stage induction

Extensive stage induction

Small cell lung cancer · 39 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 7 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Carboplatin and Paclitaxel (CP) and Ipilimumab Variant #01	—	R 788 598	21d	—	~13.4 mo	—	—	1
Carboplatin and Etoposide (CE) and Durvalumab Variant #01	—	R 265 474	28d	—	12.9 mo	—	—	2
Cisplatin and Etoposide (EP) and Durvalumab Variant #01	—	R 264 614	28d	—	12.9 mo	—	—	3
Carboplatin and Etoposide (CE) and Pembrolizumab Variant #01	—	R 84 059	21d	—	—	—	—	1
Cisplatin and Etoposide (EP) and Pembrolizumab Variant #01	—	R 83 409	21d	—	—	—	—	1
Carboplatin and Etoposide (CE) and Atezolizumab Variant #01	—	R 33 327	21d	—	12.3 mo	—	—	1
Carboplatin and Etoposide (CE) and Bevacizumab Variant #01	—	R 30 695	21d	5.5 mo	—	8	R 245 561 PFS proxy	1
Cisplatin and Etoposide (EP) and Bevacizumab Variant #01	—	R 30 045	21d	5.5 mo	—	8	R 240 357 PFS proxy	1
EP-Topotecan Variant #01	—	R 12 985	21d	—	10.2 mo	—	—	—
ICE-V Variant #01	—	R 12 190	28d	—	15.6 mo	—	—	1
ICE Variant #01	—	R 11 539	14d	—	13.9 mo	—	—	—
EVI Variant #01 Partial	—	R 11 425	21d	—	—	—	—	—
IVE Variant #01	—	R 10 872	21d	—	10.0 mo	—	—	1
VIP Variant #01	—	R 10 535	21d	—	—	—	—	—
Ifosfamide monotherapy N/A - secondary systemic drug	—	R 9 835	28d	~4.0 mo	~8.4 mo	~5	~R 49 173 PFS proxy · indirect	2
Cisplatin and Etoposide (EP) Variant #01	—	R 4 264	42d	5.0 mo	10.2 mo	4	R 17 056 PFS proxy	10
PCE Variant #01	—	R 4 157	21d	—	—	—	—	—
CEV (Carboplatin/Etoposide) Variant #01	—	R 3 016	—	—	—	—	—	—
VMV-VAC Variant #01	—	R 2 840	21d	—	—	—	—	—
CDE Variant #04	—	R 2 810	21d	4.9 mo	12.4 mo	8	R 22 477 PFS proxy	—
PCDE Variant #01	—	R 2 441	28d	—	8.7 mo	—	—	1
Carboplatin and Etoposide (CE) Variant #10	—	R 2 265	21d	4.4 mo	10.6 mo	7	R 15 853 PFS proxy	16
Carboplatin and Etoposide (CE) and Tislelizumab Variant #01 Partial	—	R 2 072	21d	—	15.5 mo	—	—	1
Carboplatin and Etoposide (CE) and Serplulimab Variant #01 Partial	—	R 2 072	21d	—	15.6 mo	—	—	2
CEV (Cyclophosphamide/Etoposide) Variant #01	—	R 2 002	21d	—	—	—	—	—
Carboplatin and Irinotecan Variant #01	—	R 1 943	21d	—	8.5 mo	—	—	1
CAVE Variant #01	—	R 1 624	21d	—	—	—	—	—
CEV (Cyclophosphamide/Epirubicin) Variant #01	—	R 1 489	21d	—	—	—	—	—
Cisplatin and Etoposide (EP) and Tislelizumab Variant #01 Partial	—	R 1 421	21d	—	15.5 mo	—	—	1
CAV/PE Variant #01	—	R 1 354	21d	—	—	—	—	—
CAV Variant #01	—	R 760	21d	—	~7.6 mo	—	—	1
Cisplatin and Irinotecan (IC) N/A - secondary systemic drug	—	R 743	42d	—	10.2 mo	—	—	3
BACO Variant #01	—	R 739	21d	—	—	—	—	—
Cyclophosphamide, Lomustine, Methotrexate Variant #01 Partial	—	R 600	42d	—	—	—	—	—
Cyclophosphamide, Lomustine, Procarbazine Variant #01 Partial	—	R 333	42d	—	—	—	—	—
Cyclophosphamide and Lomustine Variant #01 Partial	—	R 333	42d	—	—	—	—	—
Belotecan and Cisplatin Variant #01 Partial	—	R 300	21d	—	—	—	—	—
Docetaxel monotherapy N/A - secondary systemic drug	—	R 243	28d	~3.2 mo	~9.8 mo	~4	~R 973 PFS proxy · indirect	52
Teniposide monotherapy Variant #01 Partial	—	—	21d	—	—	—	—	—

39 of 39 regimens shown